The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide

Behavioral Neuroscience

Volumn 125, Issue 5, 2011, Pages 783-790

  Veeraragavan, Surabi ^a   Bui, Nghiem ^a   Perkins, Jennie R ^a   Yuva Paylor, Lisa A ^a   Paylor, Richard ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Audiogenic seizures; Behavior; Fragile X syndrome; Learning and memory; M4 receptors; Muscarinic receptors; Tropicamide

Indexed keywords

MUSCARINIC M4 RECEPTOR; T 9778; TROPICAMIDE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AUDIOGENIC SEIZURE; BEHAVIOR CONTROL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; FMR1 GENE; FRAGILE X SYNDROME; GENE; KNOCKOUT GENE; LEARNING; LOCOMOTION; MALE; MEMORY CONSOLIDATION; NONHUMAN; OPEN FIELD TEST; PASSIVE AVOIDANCE; PERSEVERATION; SENSORY GATING; TASK PERFORMANCE; WILD TYPE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; MALE; MICE; MICE, KNOCKOUT; MUSCARINIC ANTAGONISTS; RECEPTOR, MUSCARINIC M4; TROPICAMIDE;

EID: 80053607529     PISSN: 07357044     EISSN: 19390084     Source Type: Journal    
DOI: 10.1037/a0025202     Document Type: Article

References (63)

1. Adem A., Jolkkonen M., Bogdanovic N., Islam A., Karlsson E. Localization of M1 muscarinic receptors in rat brain using selective muscarinic toxin-1. Brain Research Bulletin 1997, 44:597-601. 10.1016/S0361-9230(97)00281-5.
2. Alleva E., Aloe L., Laviola G. Pretreatment of young mice with nerve growth factor enhances scopolamine-induced hyperactivity. Dev Brain Res 1986, 28:278-281. 10.1016/0165-3806(86)90032-5.
3. Bagri A., Di Scala G., Sandner G. Myoclonic and tonic seizures elicited by microinjection of cholinergic drugs into the inferior colliculus. Therapie 1999, 54:589-594.
4. Bakker C.E., Verheij C., Willemsen R., van der Helm R., Oerlemans F., Vermeij M., Willems P.J. Fmr1 knockout mice: A model to study fragile X mental retardation. Cell 1994, 78:23-33.
5. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends in Neurosciences 2004, 27:370-377. 10.1016/j.tins.2004.04.009.
6. Bouwknecht J.A., Paylor R. Pitfalls in the interpretation of genetic and pharmacological effects on anxiety-like behaviour in rodents. Behavioural Pharmacology 2008, 19:385-402. 10.1097/FBP.0b013e32830c3658.
7. Broekkamp C.L., Rijk H.W., Joly-Gelouin D., Lloyd K.L. Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. European Journal of Pharmacology 1986, 126:223-229. 10.1016/0014-2999(86)90051-8.
8. Campbell N., Boustani M., Limbil T., Ott C., Fox C., Maidment I., Gulati R. The cognitive impact of anticholinergics: A clinical review. Clin. Interv. Aging 2009, 4:225-233.
9. Caulfield M.P., Birdsall N.J. International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacological Reviews 1998, 50:279-290.
10. Caulfield M.P., Higgins G.A., Straughan D.W. Central administration of the muscarinic receptor subtype-selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouse. Journal of Pharmacy and Pharmacology 1983, 35:131-132. 10.1111/j.2042-7158.1983.tb04290.x.
11. Chen L., Toth M. Fragile X mice develop sensory hyperactivity to auditory stimuli. Neuroscience 2001, 103:1043-1050. 10.1016/S0306-4522(01)00036-7.
12. D'Antuono M., Merlo D., Avoli M. Involvement of cholinergic and gabaergic systems in the fragile X knockout mice. Neuroscience 2003, 119:9-13. 10.1016/S0306-4522(03)00103-9.
13. D'Hooge R., Nagels G., Franck F., Bakker C.E., Reyniers E., Storm K., Kooy R.F., Oostra B.A., Willems P.J., De Deyn P.P. Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience 1997, 76:367-376. 10.1016/S0306-4522(96)00224-2.
14. Dobkin C., Rabe A., Dumas R., El Idrissi A., Haubenstock H., Brown W.T. Fmr1 knockout mouse has a distinctive strain-specific learning impairment. Neuroscience 2000, 100:423-429. 10.1016/S0306-4522(00)00292-X.
15. Elrod K., Buccafusco J.J. An evaluation of the mechanism of scopolamine-induced impairment in two passive avoidance protocols. Pharmacology, Biochemistry, and Behavior 1988, 29:15-21. 10.1016/0091-3057(88)90267-5.
16. Feinstien C., Reiss A. Autism: The point of view from Fragile X studies. Journal of Autism and Developmental Disabilities 1998, 28:393-406. 10.1023/A:1026000404855.
17. Ferreira A.R., Fürstenau L., Blanco C., Kornisiuk E., Sánchez G., Daroit D., Quillfeldt J.A. Role of hippocampal M1 and M4 muscarinic receptor subtypes in memory consolidation in the rat. Pharmacology, Biochemistry and Behavior 2003, 74:411-415. 10.1016/S0091-3057(02)01007-9.
18. Fisch G.S., Hao H.K., Bakker C., Oostra B.A. Learning and memory in the FMR1 knockout mouse. American Journal of Medicine Genet 1999, 84:277-282. 10.1002/(SICI)1096-8628(19990528)84:3<277::AID-AJMG22>3.0.CO;2-W.
19. Fornari R.V., Moreira K.M., Oliveira M.G. Effects of the selective M1 muscarinic receptor antagonist dicyclomine on emotional memory. Learning and Memory 2000, 7:287-292. 10.1101/lm.34900.
20. Frankland P.W., Wang Y., Rosner B., Shimizu T., Balleine B.W., Dykens, Silva A.J. Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice. Molecular Psychiatry 2004, 9:417-425. 10.1038/sj.mp.4001432.
21. Ghelardini C., Galeotti N., Gualtieri F., Marchese V., Bellucci C., Bartolini A. Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9. Journal of Pharmacology and Experimental Therapeutics 1998, 284:806-881.
22. Gomeza J., Zhang L., Kostenis E., Felder C., Bymaster F., Brodkin J., Wess J. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. USA 1999, 96:10483-10488. 10.1073/pnas.96.18.10483.
23. Hagerman R.J., Hagerman P.J. Fragile X syndrome: Diagnosis, treatment, and research 2002, Johns Hopkins University Press, Baltimore, MD. 3rd ed.
24. Hedlund P.B., Sutcliffe J.G. The 5-HT7 receptor influences stereotypic behavior in a model of obsessive-compulsive disorder. Neuroscience Letters 2007, 414:247-251. 10.1016/j.neulet.2006.12.054.
25. Huber K.M., Gallagher S.M., Warren S.T., Bear M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. USA 2002, 99:7746-7750. 10.1073/pnas.122205699.
26. Jones C.K., Shannon H.E. Bilateral lesions of the laterodorsal tegmental nucleus disrupt prepulse inhibition of acoustic startle reflex in rats. Schizophren. Res. 1998, 29:199. 10.1016/S0920-9964(97)88812-3.
27. Lanzafame A.A., Christopoulos A., Mitchelson F. Cellular signaling mechanisms for muscarinic acetycholine receptors. Receptors and Channels 2003, 9:241-260. 10.1080/10606820308263.
28. 4 binding sites in rabbit lung, chicken heart and NG108-15 cells. Molecular Pharmacology 1990, 38:805-815.
29. Lazaris A., Cassel S., Stemmelin J., Cassel J.C., Kelche C. Intrastriatal infusions of methoctramine improve memory in cognitively impaired aged rats. Neurobiology of Aging 2003, 24:379-383. 10.1016/S0197-4580(02)00067-2.
30. Levey A.I., Kitt C.A., Simonds W.F., Price D.L., Brann M.R. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. Journal of Neuroscience 1991, 11:3218-3226.
31. Lucey J.V., Butcher G., Clare A.W., Dinan T.G. Elevated growth hormone responses to pyridostigmine in obsessive-compulsive disorder: Evidence of cholinergic supersensitivity. American Journal of Psychiatry 1993, 150:961-962.
32. Marubio L.M., Paylor R. Impaired passive avoidance learning in mice lacking central neuronal nicotinic acetylcholine receptors. Neuroscience 2004, 129:575-582. 10.1016/j.neuroscience.2004.09.003.
33. Mash D.C., Potter L.T. Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain. Neuroscience 1986, 19:551-564. 10.1016/0306-4522(86)90280-0.
34. Musumeci S.A., Bosco P., Calabrese G., Bakker C., De Sarro G.B., Elia M., Oostra B.A. Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 2000, 41:19-23. 10.1111/j.1528-1157.2000.tb01499.x.
35. Nielsen D.M., Derber W.J., McClellan D.A., Crnic L.S. Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Research 2002, 927:8-17. 10.1016/S0006-8993(01)03309-1.
36. Njung'e K., Handley S.L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Beha 1991, 38:63-67. 10.1016/0091-3057(91)90590-X.
37. Ohnuki T., Nomura Y. Effects of selective muscarinic antagonists, pirenzepine and AF-DX 116, on passive avoidance tasks in mice. Biological and Pharmaceutical Bulletin 1996, 19:814-818.
38. Oki T., Takagi Y., Inagaki S., Taketo M.M., Manabe T., Matsui M., Yamada S. Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice. Brain Research. Molecular Brain Research 2005, 133:6-11. 10.1016/j.molbrainres.2004.09.012.
39. Pandit R.J., Taylor R. Mydriasis and glaucoma: Exploding the myth. A systematic review. Diabetic Medicine 2000, 17:693-699. 10.1046/j.1464-5491.2000.00368.x.
40. Paylor R., Yuva-Paylor L.A., Nelson D.L., Spencer C.M. Reversal of sensorimotor gating abnormalities in Fmr1 knockout mice carrying a human Fmr1 transgene. Behavioral Neuroscience 2008, 122:1371-1377. 10.1037/a0013047.
41. Qin M., Kang J., Smith C.B. Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proceedings of the National Academy of Science 2002, 99:15758-15763.
42. Quirion R., Wilson A., Rowe W., Aubert I., Richard J., Doods H., Meaney M.J. Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired. Journal of Neuroscience 1995, 15:1455-1462.
43. Roldán G., Bolaños-Badillo E., González-Sánchez H., Quirarte G.L., Prado-Alcalá R.A. Selective M1 muscarinic receptor antagonists disrupt memory consolidation of inhibitory avoidance in rats. Neuroscience Letters 1997, 230:93-96. 10.1016/S0304-3940(97)00489-8.
44. Santiago M.P., Potter L.T. Biotinylated m4-toxin demonstrates more M4 muscarinic receptor protein on direct than indirect striatal projection neurons. Brain Research 2001, 894:12-20. 10.1016/S0006-8993(00)03170-X.
45. Smith R.D., Grzelak M.E., Belanger B., Morgan C.A. The effects of tropicamide on mydriasis in young rats exhibiting a natural deficit in passive-avoidance responding. Life Sciences 1996, 59:753-760. 10.1016/0024-3205(96)00361-X.
46. Soares J.C., Fornari R.V., Oliveira M.G. Role of muscarinic M1 receptors in inhibitory avoidance and contextual fear conditioning. Neurobiology of Learning and Memory 2006, 86:188-196. 10.1016/j.nlm.2006.02.006.
47. Spencer C.M., Alekseyenko O., Hamilton S.M., Thomas A.M., Serysheva E., Yuva-Paylor L.A., Paylor R. Modifying behavioral phenotypes in Fmr1 KO mice: Genetic background differences reveal autistic-like responses. Autism Research 2011, 4:40-56. 10.1002/aur.168.
48. Spencer C.M., Alekseyenko O., Serysheva E., Yuva-Paylor L.A., Paylor R. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav 2005, 4:420-430. 10.1111/j.1601-183X.2005.00123.x.
49. Spencer C.M., Graham D.F., Yuva-Paylor L.A., Nelson D.L., Paylor R. Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. Behavioral Neuroscience 2008, 122:710-715. 10.1037/0735-7044.122.3.710.
50. Swerdlow N.R., Geyer M.A. Prepulse inhibition of acoustic startle in rats after lesions of the pedunculopontine tegmental nucleus. Behavioral Neuroscience 1993, 107:104-117. 10.1037/0735-7044.107.1.104.
51. Thomas A., Burant A., Bui N., Graham D., Yuva-Paylor L.A., Paylor R. Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology 2009, 204:361-373. 10.1007/s00213-009-1466-y.
52. Thomsen M., Wess J., Fulton B.S., Fink-Jensen A., Caine S.B. Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice. Psychopharmacology 2010, 208:401-416. 10.1007/s00213-009-1740-z.
53. Turski W.A., Cavalheiro E.A., Bortolotto Z.A., Mello L.M., Schwarz M., Turski L. Seizures produced by pilocarpine in mice: A behavioral, electroencephalographic and morphological analysis. Brain Research 1984, 321:237-253. 10.1016/0006-8993(84)90177-X.
54. Ukai M., Okuda A., Mamiya T. Effects of anticholinergic drugs selective for muscarinic receptor subtypes on prepulse inhibition in mice. European Journal of Pharmacology 2004, 492(2-3):183-187. 10.1016/j.ejphar.2004.03.066.
55. Vannucchi M.G., Pepeu G. Muscarinic receptor modulation of acetylcholine release from rat cerebral cortex and hippocampus. Neuroscience Letters 1995, 190:53-56. 10.1016/0304-3940(95)11498-L.
56. Vannucchi M.G., Scali C., Kopf S.R., Pepeu G., Casamenti F. Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats. Neuroscience 1997, 79:837-846. 10.1016/S0306-4522(97)00091-2.
57. Veeraragavan S., Bui N., Perkins J.R., Yuva-Paylor L.A., Carpenter R.L., Paylor R. Modulation of behavioral phenotypes by a muscarinic M1 antagonist in a mouse model of fragile X syndrome. Psychopharmacology (Berl) 2011, [Epub ahead of print].
58. Volk L.J., Pfeiffer B.E., Gibson J.R., Huber K.M. Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation. Journal of Neuroscience 2007, 27:11624-11634. 10.1523/JNEUROSCI.2266-07.2007.
59. Vuori M.L., Kaila T., Iisalo E., Saari K.M. Systemic absorption and anticholinergic activity of topically applied tropicamide. J. Ocul. Pharmacol. 1994, 10:431-437. 10.1089/jop.1994.10.431.
60. Wada J.A., Terao A., Scholtmeyer H., Trapp W.G. Susceptibility to audiogenic stimuli induced by hyperbaric oxygenation and various neuroactive agents. Experimental Neurology 1971, 33:123-129. 10.1016/0014-4886(71)90107-5.
61. Wess J. Molecular biology of muscarinic acetylcholine receptors. Critical Reviews in Neurobiology 1996, 10:69-99.
62. Worms P., Gueudet C., Perio A., Soubrie P. Systemic injection of pirenzepine induces a deficit in passive avoidance learning in rats. Psychopharmacology 1989, 98:286-288. 10.1007/BF00444707.
63. Yan Q.J., Asafo-Adjei P.K., Arnold H.M., Brown R.E., Bauchwitz R.P. A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes, Brain and Behavior 2004, 3:337-359. 10.1111/j.1601-183X.2004.00087.x.